GeoVax Labs, Inc. (Nasdaq: GOVX) announced Monday its plans to advance Gedeptin, its gene-directed enzyme prodrug therapy, toward Phase 2 clinical initiation and potential strategic partnerships. The company highlighted that the convergence of upcoming clinical milestones and the growing focus on combination therapies in oncology creates a timely opportunity to position Gedeptin for the next stage of value creation.
Gedeptin is designed to be integrated into combination treatment regimens, particularly alongside immune checkpoint inhibitors (ICIs) and other established oncology backbones. According to the company, this approach aligns with the evolving treatment landscape and may support broader applicability across multiple tumor types. GeoVax is preparing to initiate a Phase 2 clinical trial evaluating Gedeptin in combination with an ICI as a first-line neoadjuvant treatment in patients with resectable locally advanced head and neck cancer, with trial initiation targeted for 2027. The study will evaluate tumor response in the neoadjuvant setting, biomarker-driven immune activation, and event-free survival outcomes.
“We are entering an important phase of development for Gedeptin, with a focus on clinical execution and advancing discussions around potential partnerships,” said David A. Dodd, Chairman and Chief Executive Officer of GeoVax. “As combination therapy becomes more common across oncology, we believe Gedeptin is well positioned to be integrated into these regimens and contribute to improved treatment outcomes.”
Beyond the lead clinical program, GeoVax is planning to advance preclinical and translational work evaluating Gedeptin across additional solid tumor indications. These efforts are intended to identify tumor settings where combination approaches may provide the greatest clinical benefit, support expansion beyond head and neck cancer, and inform future clinical development strategies.
The company is actively pursuing opportunities to advance Gedeptin through clinical development partnerships, combination-focused collaborations, and potential licensing or co-development arrangements. GeoVax has established a clinical and scientific foundation to support this advancement, including completed Phase 1/2 clinical experience in advanced head and neck cancer, engagement of an Oncology Advisory Board with deep immuno-oncology expertise, and expanded intellectual property supporting combination use with checkpoint inhibitors.
Gedeptin is a gene-directed enzyme prodrug therapy delivered intratumorally using a non-replicating viral vector encoding purine nucleoside phosphorylase. Following administration of a systemically delivered prodrug, the encoded enzyme converts the prodrug into a cytotoxic agent directly within the tumor microenvironment.
The importance of this announcement lies in the potential for Gedeptin to address a critical need in oncology: enhancing the efficacy of immune checkpoint inhibitors, which have become a standard of care for many cancers but still leave a significant proportion of patients unresponsive. By combining Gedeptin with ICIs, GeoVax aims to improve treatment outcomes and expand the applicability of immunotherapy to more patients. The planned Phase 2 trial represents a key step in establishing clinical validation for this combination strategy.
For the biotech industry, successful development of Gedeptin could open new avenues for combination therapy, potentially increasing the value of existing checkpoint inhibitors and offering a novel approach to treating solid tumors. The company’s focus on partnerships suggests that GeoVax is looking to leverage external expertise and resources to accelerate development, which could be a model for other small biotechs navigating the complex oncology landscape.
More information about GeoVax and its programs can be found at www.geovax.com.
